secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jounce Therapeutics, Inc. (—)
CIK:        0001640455
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001640455-23-000093
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jounce Therapeutics acquired by Concentra Biosciences for $1.85/share + CVR; tender closed at 69.09%
--------------------------------------------------------------------------------

- Tender offer closed with 69.09% of shares validly tendered, meeting minimum condition.
- Merger completed under Section 251(h); shareholders received $1.85 cash plus one CVR per share.
- Shares to be delisted from Nasdaq; company will file Form 15 to suspend SEC reporting.
- Board members resigned, replaced by Kevin Tang as sole director and officer.
- Lease for Cambridge HQ terminated; contingent termination fee of $5.25M refundable if new tenant found by July 2, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640455/000164045523000093/0001640455-23-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640455/000164045523000093/jnce-20230502.htm
  HTML page:      https://secwatch.observer/filing/0001640455-23-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer